模型分歧时:协调肺炎球菌疫苗接种成本效果分析以指导美国成人PCV20和PCV21的使用
研究系统比较了两个已发表的决策模型,评估50岁及以上成人使用20价和21价肺炎球菌结合疫苗(PCV20/PCV21)的成本效果。初始结果差异很大,主要由疾病风险、接种可能性、血清型覆盖和儿童接种的间接效应等不确定参数驱动。通过协调策略和参数,结果显著趋同,表明模型比较可识别不确定性并改善决策。
要点
- 两个模型初始成本效果结果差异大,源于疾病风险、接种可能性等不确定参数。
- 参数协调后结果显著趋同,疫苗效果假设、队列年龄等也影响分歧。
- 模型比较可识别不确定性、揭示证据缺口并提高决策透明度。
核心结论
- 通过协调模型参数和策略,两个肺炎球菌疫苗成本效果模型的结果分歧得以减小。
- 成本效果比对各模型输入参数非常敏感,模型比较有助于识别不确定性和证据缺口。
研究设计与样本
- 系统比较两个已发表的决策模型,评估PCV20和PCV21在50岁及以上成人中的成本效果。
- 通过迭代修改Markov决策模型结构、参数和假设,并做敏感性分析来协调模型。
主要发现
- 初始结果差异广泛,由疾病风险、接种可能性、血清型覆盖和儿童接种间接效应驱动。
- 结果对参数变异极度敏感,因策略间增量差异微小。
- 参数协调后结果显著趋同;疫苗效果假设、队列年龄和单年龄与多年龄队列也减少分歧。
临床怎么用
- 决策者应意识到肺炎球菌疫苗成本效果模型结果可能因参数假设不同而差异很大。
- 模型比较和协调可用于识别不确定性、揭示证据缺口,并可能改善疫苗接种决策。
局限性
- 原文未明确报告模型比较的具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Policymakers use decision models to assess pneumococcal vaccine cost-effectiveness, but different models often yield inconsistent results. We systematically compared 2 published models evaluating 20- and 21-valent pneumococcal conjugate vaccines (PCV20/PCV21) in adults aged 50+ years. METHODS: Markov decision model structures, parameters, and assumptions were iteratively modified, comparing PCV20 use in higher-risk 50-64-year-olds and all 65-year-olds to either PCV20 or PCV21 for all at age 50 or 65. One model was adjusted toward the other by harmonizing strategies, aligning parameter values, performing sensitivity analyses to identify influential parameters, and modifying sensitive parameters to narrow differences. Other analyses compared differing cohort structures and vaccine timing. RESULTS: Initial results diverged widely, driven by differing disease risk, vaccination likelihood and serotype coverage, and childhood vaccination indirect effects - all uncertain and debated. Results were extremely sensitive to parameter variation due to minuscule incremental differences between strategies. Parameter harmonization produced substantial convergence. Other factors that reduced divergence were vaccine effectiveness assumptions, cohort age, and single-age vs. multi-age cohorts. CONCLUSION: Divergent model results were mitigated through harmonization. Cost-effectiveness ratios were very sensitive to alternative model inputs. Model comparisons can identify uncertainty, reveal evidence gaps, enhance transparency, and potentially improve decision making.
引用
- Smith KJ, Wateska AR, Yi Z, et al. When models diverge: Harmonizing pneumococcal vaccination cost-effectiveness analyses to inform PCV20 and PCV21 use in US adults. Vaccine. 2026. PMID: 42892161. doi:10.1016/j.vaccine.2026.129267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。